naa a22 4500 510739040 CHVBK 20180411083021.0 cr unu---uuuuu 180411e20131201xx s 000 0 eng 10.1007/s12015-013-9464-1 doi (NATIONALLICENCE)springer-10.1007/s12015-013-9464-1 In Vivo Ectopic Implantation Model to Assess Human Mesenchymal Progenitor Cell Potential [Elektronische Daten] [Ander Abarrategi, Raquel Perez-Tavarez, Miguel Rodriguez-Milla, Isabel Cubillo, Francisca Mulero, Arantzazu Alfranca, Jose Lopez-Lacomba, Javier García-Castro] Clinical interest on human mesenchymal progenitor cells (hMPC) relies on their potential applicability in cell-based therapies. An in vitro characterization is usually performed in order to define MPC potency. However, in vitro predictions not always correlate with in vivo results and thus there is no consensus in how to really assess cell potency. Our goal was to provide an in vivo testing method to define cell behavior before therapeutic usage, especially for bone tissue engineering applications. In this context, we wondered whether bone marrow stromal cells (hBMSC) would proceed in an osteogenic microenvironment. Based on previous approaches, we developed a fibrin/ceramic/BMP-2/hBMSCs compound. We implanted the compound during only 2weeks in NOD-SCID mice, either orthotopically to assess its osteoinductive property or subcutaneously to analyze its adequacy as a cell potency testing method. Using fluorescent cell labeling and immunohistochemistry techniques, we could ascertain cell differentiation to bone, bone marrow, cartilage, adipocyte and fibrous tissue. We observed differences in cell potential among different batches of hBMSCs, which did not strictly correlate with in vitro analyses. Our data indicate that the method we have developed is reliable, rapid and reproducible to define cell potency, and may be useful for testing cells destined to bone tissue engineering purposes. Additionally, results obtained with hMPCs from other sources indicate that our method is suitable for testing any potentially implantable mesenchymal cell. Finally, we propose that this model could successfully be employed for bone marrow niche and bone tumor studies. The Author(s), 2013 Mesenchymal cells nationallicence Ceramics nationallicence BMP-2 nationallicence Animal model nationallicence Abarrategi Ander Unidad de Biotecnología Celular, Instituto de Investigación en Enfermedades Raras, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km. 2.200, Majadahonda, Madrid, Spain aut Perez-Tavarez Raquel Unidad de Biotecnología Celular, Instituto de Investigación en Enfermedades Raras, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km. 2.200, Majadahonda, Madrid, Spain aut Rodriguez-Milla Miguel Unidad de Biotecnología Celular, Instituto de Investigación en Enfermedades Raras, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km. 2.200, Majadahonda, Madrid, Spain aut Cubillo Isabel Unidad de Biotecnología Celular, Instituto de Investigación en Enfermedades Raras, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km. 2.200, Majadahonda, Madrid, Spain aut Mulero Francisca Spanish National Cancer Research Centre, Madrid, Spain aut Alfranca Arantzazu Unidad de Biotecnología Celular, Instituto de Investigación en Enfermedades Raras, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km. 2.200, Majadahonda, Madrid, Spain aut Lopez-Lacomba Jose Instituto de Estudios Biofuncionales, Universidad Complutense, Madrid, Spain aut García-Castro Javier Unidad de Biotecnología Celular, Instituto de Investigación en Enfermedades Raras, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km. 2.200, Majadahonda, Madrid, Spain aut Stem Cell Reviews and Reports Springer US; http://www.springer-ny.com 9/6(2013-12-01), 833-846 1550-8943 9:6<833 2013 9 12015 https://doi.org/10.1007/s12015-013-9464-1 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12015-013-9464-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Abarrategi Ander Unidad de Biotecnología Celular, Instituto de Investigación en Enfermedades Raras, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km. 2.200, Majadahonda, Madrid, Spain aut NATIONALLICENCE 700 1- Perez-Tavarez Raquel Unidad de Biotecnología Celular, Instituto de Investigación en Enfermedades Raras, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km. 2.200, Majadahonda, Madrid, Spain aut NATIONALLICENCE 700 1- Rodriguez-Milla Miguel Unidad de Biotecnología Celular, Instituto de Investigación en Enfermedades Raras, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km. 2.200, Majadahonda, Madrid, Spain aut NATIONALLICENCE 700 1- Cubillo Isabel Unidad de Biotecnología Celular, Instituto de Investigación en Enfermedades Raras, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km. 2.200, Majadahonda, Madrid, Spain aut NATIONALLICENCE 700 1- Mulero Francisca Spanish National Cancer Research Centre, Madrid, Spain aut NATIONALLICENCE 700 1- Alfranca Arantzazu Unidad de Biotecnología Celular, Instituto de Investigación en Enfermedades Raras, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km. 2.200, Majadahonda, Madrid, Spain aut NATIONALLICENCE 700 1- Lopez-Lacomba Jose Instituto de Estudios Biofuncionales, Universidad Complutense, Madrid, Spain aut NATIONALLICENCE 700 1- García-Castro Javier Unidad de Biotecnología Celular, Instituto de Investigación en Enfermedades Raras, Instituto de Salud Carlos III, Carretera Majadahonda-Pozuelo km. 2.200, Majadahonda, Madrid, Spain aut NATIONALLICENCE 773 0- Stem Cell Reviews and Reports Springer US; http://www.springer-ny.com 9/6(2013-12-01), 833-846 1550-8943 9:6<833 2013 9 12015 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer